Listen to this content

After its decriminalization in many parts of the world, cannabis has been a popular investment among financial markets, but experts agree that cannabis’s time in the spotlight is coming to an end, making way for the psilocybin industry’s ride to stardom.

Thanks to decades of heavy research and countless studies, psilocybin  (commonly refered to as “shrooms” or “magic mushrooms”) have finally entered society’s collective consciousness as a medicinal substance that has the power to improve people’s lives, effectively shedding its negative persona as being taboo and dangerous.

Canada sees a spike in scientific interest in psilocybin mushrooms

In the last decade, Canada has seen slow but steady progress in studies about how microdosing psychedelics like mushrooms capsules have the potential to successfully treat those with mood disorders like depression, anxiety, and PTSD.

What is microdosing?

According to Biomed Central, microdosing is “the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance”. Many people that support microdosing in Canada have said that they increased the overall quality of life after microdosing mushroom capsules, by lessening their levels of anxiety and bringing a clearer, more present state of mind.

The benefits that come from microdosing psilocybin have lead experts to believe that legalization of psilocybin mushrooms is a very likely event to come in the near future.

Psilocybin mushroom prescriptions

As a result, biopharmaceutical companies all over Canada have been racing to develop psychedelic-based prescriptions. Buying mushroom capsules from a medicinal mushroom dispensary is already possible if you have a terminal illness or meet other extreme requirements. But Canadians are pushing to make the buying of medicinal mushroom capsules a much easier process for all.

The scientifically-proven benefits that could be harnessed by so many from medicinal mushroom capsules are swaying investors to step away from the once-promising cannabis industry into the psilocybin mushroom industry.

While the two industries are different in complex ways, there are still some similarities between the two.

Cannabis vs psilocybin – the differences and similarities between the two industries

While both psilocybin mushrooms and cannabis are currently still considered illegal under federal law in countries around the world, the two industries are actually pretty different from one another.

Both substances are still considered “recreational” by many,  but those who are in the know, understand that psilocybin and other forms of psychedelics, hold much more potential for revolutionizing how health professionals can treat mental health. This makes psilocybin appealing for those that want to invest in something deeper and more long-lasting than a popular recreational substance.

Cannabis does have medicinal properties as well and is rightly sold and marketed for that reason but not to the same extent as psilocybin. If scientist and medical officials have their way, microdosing Canada would be used as a mental health and wellness prescription, not as an entertainment-based market like cannabis often is.

Microdosing Canada and the potential for investors

The driving force behind what makes investing in the psilocybin mushroom industry so promising is the fact the microdosing Canada and the legalization of medicinal mushroom capsules aren’t trying to build off of the same idea that the cannabis industry has.

Going to a medicinal mushroom dispensary will be more like going to a pharmacy, where doctors will be prescribing microdosing as a form of mental health treatment. And mental health is what it all comes down to.

Mental health and well being

With the current mental health crisis making life difficult for so many around the world, investors in microdosing Canada see a unique opportunity to not only invest in it for huge financial gains, but also for the betterment of mental health and the well being of not just Canadians but also people all around the world. 

Investing in education around the use of psychedelics for mental health is something that investors are taking very seriously, as many people hold outdated views about how psilocybin affects the body and mind. Catching the world up with the current scientific findings is just as important as funding the endeavor of studying psilocybin further.

The future of buying shrooms in Canada looks bright

When people finally catch on, as so many people already have, the benefits that society and investors could both see are huge. But the world will never reach that point unless people, investors, and governments all get on the same page.

Nailing down a solid number for potential market value is difficult at this early stage, but analysts predict that the total value from the psychedelic industry could easily reach $100 billion.